Tandon Vishal R, Mahajan Annil, Khajuria Vijay, Gillani Zahid H
Department of Pharmacology and Therapeutic, Government Medical College, Jammu, Jammu and Kashmir, India.
Department of General Medicine, Government Medical College, Jammu, Jammu and Kashmir, India.
J Pharmacol Pharmacother. 2014 Jul;5(3):214-6. doi: 10.4103/0976-500X.136113.
The risk for angioedema has been suggested lower with angiotensin receptor blockers (ARBs) than with angiotensin-converting enzyme inhibitors (ACEIs) or aliskiren. Many isolated reports do exist, reporting angioedema with ARBs such as olmesartan, valsartan, losartan and telmisartan. To the best of our knowledge this is the first case report of telmisartan plus ramipril fixed dose combination leading to angioedema from India questioning the rationality of ARBs plus ACEIs combination in the treatment of hypertension.
有研究表明，血管紧张素受体阻滞剂（ARB）引起血管性水肿的风险低于血管紧张素转换酶抑制剂（ACEI）或阿利吉仑。确实存在许多孤立的报告，报道了使用奥美沙坦、缬沙坦、氯沙坦和替米沙坦等ARB引起血管性水肿的情况。据我们所知，这是印度首例关于替米沙坦加雷米普利固定剂量组合导致血管性水肿的病例报告，对ARB加ACEI联合治疗高血压的合理性提出了质疑。
